Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF EQUITY

v3.21.1
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment
Common Stock
Treasury
Additional Paid-In Capital
Accumulated Other Comprehensive Loss
Accumulated Deficit
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Beginning balance, shares (in shares) at Dec. 31, 2019     670,378,701 549,907        
Beginning balance at Dec. 31, 2019 $ 1,614,759 $ (1,342) $ 6,704 $ (1,791) $ 3,142,993 $ (22,070) $ (1,511,077) $ (1,342)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Equity-based compensation expense 2,451       2,451      
Net income (loss) (59,132)           (59,132)  
Other comprehensive income (loss) (8,117)         (8,117)    
Ending balance, shares (in shares) at Mar. 31, 2020     670,378,701 549,907        
Ending balance at Mar. 31, 2020 1,548,619   $ 6,704 $ (1,791) 3,145,444 (30,187) (1,571,551)  
Beginning balance, shares (in shares) at Dec. 31, 2020     670,585,576 549,907        
Beginning balance at Dec. 31, 2020 1,671,551   $ 6,706 $ (1,791) 3,152,694 (4,225) (1,481,833)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Equity-based compensation expense 2,647       2,647      
Exercise of Common Stock options and warrants (in shares)     117,500          
Exercise of Common Stock options and warrants 308   $ 1   307      
Net income (loss) 31,078           31,078  
Other comprehensive income (loss) (9,070)         (9,070)    
Ending balance, shares (in shares) at Mar. 31, 2021     670,703,076 549,907        
Ending balance at Mar. 31, 2021 $ 1,696,514   $ 6,707 $ (1,791) $ 3,155,648 $ (13,295) $ (1,450,755)